Why vaccines are not the answer - The failure of V520 and the importance of cell-mediated immunity in the fight against HIV

Medical Hypotheses

Volumn 71, Issue 6, 2008, Pages 909-913

  White, Aaron ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; UNCLASSIFIED DRUG; V520 VACCINE;

ANTIBODY PRODUCTION; ARTICLE; CELL INFILTRATION; CELL LABELING; CELLULAR IMMUNITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; PRIORITY JOURNAL; PROPHYLAXIS; PROTEIN ANALYSIS; TREATMENT FAILURE; VACCINATION;

AIDS VACCINES; ANTIBODIES, VIRAL; HIV; HIV INFECTIONS; HUMANS; IMMUNITY, CELLULAR; IMMUNOLOGIC MEMORY; T-LYMPHOCYTES, CYTOTOXIC; TREATMENT FAILURE;

ADENOVIRIDAE;

EID: 54049085689     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2008.07.027     Document Type: Article

References (12)

1. Kaiser Daily HIV/AIDS Report. Trials of NIH HIV vaccine candidate scaled down after failure of Merck vaccine. Originally published March 25, 2008. http://www.kaisernetwork.org/Daily_reports/rep_index.cfm?DR_ID=51109; 2008 [acessed 15.05.08].
2. Watkins D.I. Basic HIV vaccine development. Top HIV Med 16 1 (2008) 7-8
3. Sekaly R.P. The failed HIV Merck vaccine study: a step back or a launching point for future vaccine development. J Exp Med 205 (2008) 7-12
4. White A.M. A Guide to Transfer Factors and Immune System Health (2007), BookSurge Publishing, North Charleston, SC
5. Corey L., McElrath M.J., Weinhold K., Matthews T., Stablein D., Graham B., et al. Cytotoxic T cell and neutralizing antibody responses to human immunodeficiency virus type 1 envelope with a combination vaccine regimen. AIDS Vaccine Evaluation Group. J Infect Dis 177 2 (1998) 301-309
6. Estrada-Parra S., Nagaya A., Serrano E., Rodriguez O., Santamaria V., Ondarza R., et al. Comparative study of transfer factor and acyclovir in the treatment of herpes zoster. Int J Immunopharmacol 20 10 (1998) 521-535
7. Xu Y.P., Zou W.M., Zhan X.J., Yang S.H., Xie D.Z., and Peng S.L. Preparation and determination of immunological activi-ties of anti-HBV egg yolk extraction. Cell Mol Immunol 3 1 (2006) 67-71
8. Pizza G., Amadori M., Ablashi D., De Vinci C., and Viza D. Cell mediated immunity to meet the avian influenza A (H5N1) challenge. Med Hypotheses 67 3 (2006) 601-608
9. Granitov V.M., Karbysheva N.V., Sultanov L.V., McCausland C., and Oganova E. Usage of Transfer Factor Plus in Treatment of HIV Infected Patients. Russ J HIV AIDS Relat Prob 1 (2002) 79-80
10. Carey J.T., Lederman M.M., Toossi Z., Edmonds K., Hodder S., Calabrese L.H., et al. Augmentation of skin test reactivity and lymphocyte blastogenesis in patients with AIDS treated with transfer factor. JAMA 257 5 (1987) 651-655
11. Guerra Raise.E., Viza L., Pizza D., De Vinci G., Schiattone ML C., Cicognani Rocaccio.L., et al. Preliminary results in HIV1-infected patients treated with transfer factor (TF) and zidovudine (ZDV). Biotherapy 9 1-3 (1996) 49-54
12. Fernandez-Ortega C., Dubed M., Ramos Y., Navea L., Alvarez G., Lobaina L., et al. Non-induced leukocyte extract reduces HIV replication and TNF secretion. Biochem Bioph Res Co 325 3 (2004) 1075-1081